Filgrastim

Pre-clinicalTerminated

0 views this week 0 watching💤 Quiet

Interest: 18/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Graft-Versus-Host Disease

Conditions

Graft-Versus-Host Disease

Trial Timeline

Feb 1, 2003 → Sep 1, 2008

NCT ID

NCT00501228

About Filgrastim

Filgrastim is a pre-clinical stage product being developed by Amgen for Graft-Versus-Host Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT00501228. Target conditions include Graft-Versus-Host Disease.

What happened to similar drugs?

0 of 6 similar drugs in Graft-Versus-Host Disease were approved

Approved (0) Terminated (0) Active (6)

🔄Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)IncytePhase 3

🔄INCA034176 + Best Available Therapy (BAT)IncytePhase 3

🔄INCA034176IncytePhase 3

🔄Itacitinib + Placebo + Prednisone + MethylprednisoloneIncytePhase 3

🔄INCA034176 + Placebo + CorticosteroidsIncytePhase 3

🔄Ruxolitinib + Extracorporeal photopheresis (ECP) + Low-dose methotrexate (MTX) + Mycophenolate mofetil (MMF) + mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) + Infliximab + Rituximab + Pentostatin + Imatinib + IbrutinibIncytePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00002126	Phase 2	Completed	—	—	HIV Infections
NCT00115128	Pre-clinical	Completed	Nov 1, 2003	Sep 1, 2007	Normal PBPC Donors
NCT00501228	Pre-clinical	Terminated	Feb 1, 2003	Sep 1, 2008	Graft-Versus-Host Disease

Competing Products

20 competing products in Graft-Versus-Host Disease

See all competitors

Product	Company	Stage	Hype Score
Alefacept	Astellas Pharma	Phase 2	27
EQ001 + EQ001 Placebo	Biocon	Phase 1/2	32
SHR0302	Jiangsu Hengrui Medicine	Phase 1	29
Prednisone + Jakavi(ruxolitinib) + Prednisone	Novartis	Phase 2	42
PredEver	Novartis	Phase 2	35
Lifitegrast 5% Ophthalmic Solution + Placebo	Novartis	Phase 1	29
LBH589 + Methylprednisolone	Novartis	Phase 2	27
Panobinostat (LBH589)	Novartis	Phase 1/2	32
AMG 592	Amgen	Phase 1	29
AMG 592	Amgen	Phase 1	29
BMS-986004 + Sirolimus + Tacrolimus	Bristol Myers Squibb	Phase 1	29
Belumosudil (KD025)	Sanofi	Phase 2	27
Belumosudil 200 mg QD + Belumosudil 200 mg BID + Belumosudil 400 mg QD	Sanofi	Phase 2	35
AAT + Placebo	CSL	Phase 2/3	42
Ruxolitinib + Methylprednisolone	Incyte	Phase 2	39
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)	Incyte	Phase 3	44
Itacitinib + Corticosteroids	Incyte	Phase 1/2	21
Ruxolitinib	Incyte	Pre-clinical	23
Itacitinib + Corticosteroid	Incyte	Phase 1	26
INCA034176	Incyte	Phase 1/2	36